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This Journal feature begins with a case vignette highlighting a common clinical problem. 
Evidence supporting various strategies is then presented, followed by a review of formal guidelines,  
when they exist. The article ends with the author’s clinical recommendations. 
An audio version 
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A 33-year-old woman presents with redness of the hands and reports the intermittent 
occurrence of tiny vesicles, scaling, and fissuring, accompanied by itching on the 
palms, fingers, and dorsal sides of the hands. She has two young children and works 
as a nurse in a nearby hospital. She has a history of childhood eczema and a contact 
allergy to nickel. How should this case be managed?
The Clinical Problem
Hand eczema, also called hand dermatitis, is an inflammation of the skin of the 
hands; some persons with hand eczema may also have foot eczema. Typical clinical 
signs are redness, infiltration of the skin, scaling, edema, vesicles, areas of hyper-
keratosis, cracks (fissures), and erosions (Fig. 1A and 1B).1 It is common, with a point 
prevalence of 4% among adults in the general population, and a 1-year prevalence of 
up to 10%, depending on whether the disease definition includes mild cases.2 The 
incidence of work-related cases (which are usually more severe than cases in the gen-
eral population) that are reported to occupational health authorities is between 0.7 and 
1.5 cases per 1000 workers per year, with much higher incidences among certain oc-
cupations, such as hairdressing.3
Manifestations of hand eczema tend to vary in severity and appearance over time. 
Cracks and blisters may partially or completely prevent the performance of manual 
work, resulting in disability and economic loss.4,5
The most common external cause of hand eczema is contact with mild toxic agents 
or irritants (e.g., water and soaps), causing irritant contact dermatitis. Allergic con-
tact dermatitis is less common than irritant contact dermatitis and reflects a contact 
allergy to a specific substance, such as rubber, nickel, or perfumes. Atopic dermatitis 
is an endogenous cause of hand eczema; one third to one half of patients with hand 
eczema may have atopy, and atopy may be manifested exclusively as dermatitis of the 
hands.2 In many patients, hand eczema has more than one cause. In addition, there 
are several types of hand eczema with no known cause (Table 1). These are hyper-
keratotic eczema (Fig. 1C), recurrent vesicular hand eczema (pompholyx, dyshidrotic 
eczema) (Fig. 1D), nummular eczema (Fig. 1E), and pulpitis (chronic fingertip derma-
titis) (Fig. 1F). (Additional images are shown in the Supplementary Appendix, avail-
able with the full text of this article at NEJM.org.) The terms dyshidrotic eczema and 
pompholyx are sometimes reserved for acute vesicular hand eczema as opposed to 
chronic vesicular hand eczema.
Strategies and Evidence
Diagnosis
A thorough patient history is essential to diagnosis, especially with respect to expo-
sure to irritants and allergens at home or at the workplace. The presence of children 
in the household (with associated exposures to soaps and detergents), occupations 
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requiring frequent hand washing, and the use of 
occlusive gloves are recognized risk factors.12 
Contact allergens may be present in domestic and 
occupational products. A history of atopic derma-
titis also predisposes patients to hand eczema.
Hand eczema may be confused with other skin 
conditions (Table 2), most frequently psoriasis and 
mycosis. Psoriasis is generally characterized by 
sharply demarcated lesions, the absence of itch-
ing, and the absence of vesicles (Fig. 2A). Hand 
eczema with infection may be confused with 
palmoplantar pustulosis, which is regarded by 
some experts as a variant of psoriasis (Fig. 2B). 
A skin biopsy of the palm is unlikely to help in 
distinguishing psoriasis from eczema. Fungal 
infection (mycosis) should always be ruled out 
by scraping some flakes for staining or culture, 
especially if only one hand is affected (Fig. 2C). 
Figures 2D and 2E show other conditions that 
mimic hand eczema.
Current classification systems for hand ecze-
ma are based on clinical and etiologic factors 
(Table 1)6-8 and have been useful for outpatient 
populations.13,14 Scoring systems based on the 
severity of symptoms have been developed but 
are not routinely used in practice.15 Cases are 
classified according to cause when possible, with 
the acknowledgment that different causes of hand 
eczema may be indistinguishable on examination. 
In many cases, the clinician is restricted to a mor-
phologic description.
Additional evaluation (beyond taking a detailed 
history) should be considered for patients in whom 
the causes of hand eczema remain undetermined. 
Patch testing may be useful in identifying a con-
tact allergy to external agents.10 Both the Amer-
ican Contact Dermatitis Society and the European 
Society of Contact Dermatitis recommend the use 
of standard screening trays (a baseline series) that 
contain the contact allergens that are most com-
monly found in the home and workplace (e.g., 
metals, rubber additives, glues, and the antibac-
terial and antimold agents in cosmetics).16 Patch 
testing is recommended in all patients with chron-
ic hand eczema. The sensitivity and specificity of 
patch testing depend on the patient’s history and 
clinical appearance; according to a retrospective 
analysis conducted in the United States, expand-
ing the standard number of test allergens would 
improve the rate of detection of contact allergic 
reactions from about 25% to about 50%.17
Prick testing, or determining allergen-specific 
IgE levels in the serum, is generally of limited 
value,18 although it is informative in cases of pro-
tein contact dermatitis (Table 1) or contact urti-
caria caused by latex proteins or fish proteins 
(Fig. 2F). Recurrent contact urticaria can become 
eczematous (e.g., in persons handling food), 
making clinical diagnosis difficult; in such cases, 
prick testing can be valuable. Testing for sensitiv-
ity to inhalation allergens (e.g., the house-dust 
mite, cat dander, or pollen) is not recommended, 
since there is insufficient evidence showing that 
exposure to such allergens provokes or sustains 
hand eczema.
Treatment
Although it would seem logical to assume that 
identifying and eliminating the causative factor 
could cure hand eczema, this feat is rarely accom-
plished in practice because the cause of disease, 
especially in patients with chronic hand eczema, 
key Clinical points
Hand Eczema
• Prompt intervention is required in patients with hand eczema because it has a tendency to become chronic.
•  In most cases, hand eczema reflects a combination of irritant contact dermatitis and endogenous factors (such as atopy), 
but contact allergy should be ruled out.
•  Avoidance of irritants (and allergens, if relevant), frequent application of lipid-rich emollients (ointments), and the use of 
topical glucocorticoids are first-line treatments, although data from randomized trials on the benefits of these and other 
treatment options are limited.
•  For patients with symptoms that are unresponsive to these initial therapies, options include phototherapy (where available) 
or oral retinoids (the latter are particularly helpful in patients with hyperkeratotic eczema).
•  Oral immunosuppressive agents (usually cyclosporine) are a final resort. Oral glucocorticoids should be used only in short 
courses to achieve rapid control.
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is often multifactorial. Nevertheless, treatment 
will be unsuccessful if causative or contributing 
factors are not eliminated.
Prompt treatment is recommended because 
hand eczema has a tendency to become chronic, 
in which case resistance to topical treatment is 
common.19 Current treatment strategies are largely 
based on clinical experience and may differ from 
country to country.7,8,20 Few therapies have been 
evaluated in randomized, controlled trials,21 and 
the trials that have been conducted typically have 
not distinguished types of eczema. Figure 3 shows 
an algorithm for the management of hand eczema.
Moisturizers, Emollients, and Skin Protection
The frequent application of emollients and mois-
turizers is routinely recommended; in many ran-
domized trials of other treatments for hand ec-
zema, the use of emollients was allowed or 
encouraged in both treatment groups. Ointments 
are preferred over creams, because creams may 
contain potentially sensitizing preservatives and 
mildly irritating emulsifiers. In one small ran-
domized trial that compared the efficacy of two 
emollients — a petrolatum-based emollient and 
an emollient containing ceramide (a skin lipid) 
— there was similar improvement in the two 
treatment groups at 2 months.23 Another trial of 
2 weeks’ duration reported a nonsignificant ben-
efit from the addition of a urea-containing mois-
turizer to a topical glucocorticoid (betamethasone) 
as compared with the use of topical betametha-
sone alone.24 Barrier creams are often recom-
mended for the prevention of occupational con-
tact dermatitis, but a Cochrane systematic review 
concluded that there is insufficient evidence that 
such creams have a long-term protective effect.25 
A more recent trial involving 255 hospital workers 
with hand eczema showed a benefit from skin-
care education and individual counseling.26 The 
interventions included oral and written instruc-
tions regarding the use of gloves and recommen-
dations on the avoidance of irritants at work and 
at home.
Job counselors should discourage employees 
from becoming exposed to irritants at work (es-
pecially in “wet work” — e.g., work that involves 
exposure of the hands to liquids, soaps, deter-
gents, cutting oils, or vegetable juices); counselors 
should simultaneously encourage adequate skin-
protection measures.27 The role of protective gloves 
is controversial. Although gloves offer protection 
from irritants (especially during “wet work”), 
prolonged occlusion may itself be a risk factor 
for hand eczema.28 In accordance with practical 
experience and support from an experimental 
study involving volunteers without hand eczema, 
a cotton lining or inner glove is recommended.29
Topical Glucocorticoids
Potent topical glucocorticoids are first-line phar-
macologic treatment for hand eczema, although 
there are limited data from randomized, controlled 
trials to confirm their efficacy. In an open-label 
study, topical mometasone furoate was applied 
freely for up to 9 weeks by patients with hand 
C Hyperkeratotic Hand Eczema
E Nummular Eczema
A Irritant Contact Dermatitis
D Recurrent Vesicular Dermatitis
F Pulpitis
B Irritant Contact Dermatitis 
with Atopic Hand Eczema
Manifested as vesicular hand eczema.
Notable for the absence of inflammatory
redness.
Manifested as coin-shaped eczematous
lesions.
Manifested as dry, red, scaling skin. 
These types of dermatitis and 
eczema often appear together.
Manifested as large vesicles on the
palms. Also called classic pompholyx
or dyshidrotic eczema.
Manifested as a dry, fissured, scaling 
without vesicles. In children may be
atopic dermatitis; in adults, although
attributed by some to friction, the
cause is often unknown. Also called
chronic fingertip dermatitis.
Figure 1. Irritant Contact Dermatitis, Atopic Hand Eczema, and Other Types 
of Hand Eczema.
Panels A through F show various types of hand eczema.
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eczema; almost half of patients had clearing at 
3 weeks, and another quarter at 6 weeks. Those 
who had clearing of eczema then participated in 
a trial of maintenance therapy for up to 36 weeks. 
Participants underwent randomization to one of 
three groups: one in which topical mometasone 
furoate was applied three times a week, a second 
in which it was applied two times a week, and a 
third in which emollients alone were applied 
freely. Recurrence-free rates were significantly 
higher in the groups receiving a glucocorticoid 
(83% and 68%, respectively) than in the group 
Table 1. Etiologic and Morphologic Classifications of Hand Eczema.*
Etiologic Classification Comments
Irritant contact dermatitis Repeated exposure to irritants (mild toxic agents) over a prolonged period may cause an inflammatory response 
of the skin, compromising the skin’s barrier function and making it susceptible to the development of con-
tact allergy. In most patients there is a history of exposure to “wet” work (contact with soaps or solvents) 
or prolonged use of occlusive gloves.
There are no clinically useful tests to assess reactions to irritants; diagnosis is often based on the absence of 
contact allergy, which is determined with the use of patch testing.
Atopic hand dermatitis Patients often have a history of asthma, hay fever, or “childhood eczema” (atopic dermatitis in childhood).
Both prick testing with inhalation or food allergens and determination of serum IgE levels are of limited value 
and not routinely recommended.
Because the barrier function of the skin is compromised, patients are predisposed to irritant contact  
dermatitis.
Allergic contact dermatitis This condition generally reflects a delayed-type, T-lymphocyte–mediated contact allergy to a chemical  
substance.
Typical contact allergens include nickel (e.g., in tools or jewelry), chromate (e.g., in leather or cement), rubber 
additives (e.g., in gloves), and preservatives (e.g., in creams or cosmetics).
Ingestion of a substantial amount of the allergen (e.g., nickel) may also provoke hand eczema, but its occur-
rence is rare.9
Diagnosis is supported by a history of exposure in combination with a positive reaction to patch testing with 
contact allergens.10
Hybrid hand eczema This type of eczema combines aspects of irritant contact dermatitis, atopic hand dermatitis, and allergic con-
tact dermatitis.
Protein contact dermatitis This subtype of allergic contact dermatitis frequently occurs in patients in professions involving food. Initially, 
the reaction to proteins is urticarial (contact urticaria), but eczema may develop. IgE reactions to specific 
proteins are often (but not always) detected with prick tests or serum analysis. Latex allergy is a related 
phenomenon.
Unclassified In patients with chronic hand eczema, the original causative factor tends to become irrelevant.
Morphologic
Recurrent vesicular, or dys-
hidrotic, hand eczema; 
pompholyx
The classic presentation is an eruption of large vesicles on the palms that tends to recur; it also includes recur-
rent vesicular eruptions on the palms and the palmar and lateral sides of the fingers, which is known as 
macrovesicular eczema (these patients often also have eruptions on the soles of the feet). The name dyshi-
drotic eczema is a misnomer, since the condition is not related to the sweat glands. The cause is unknown. 
A contact allergic reaction or atopic hand eczema may also be manifested as an identical vesicular erup-
tion; in such cases, etiologic classification is preferable.
Hyperkeratotic hand  
eczema
Sharply demarcated areas of thick scaling or hyperkeratosis on the palms (and frequently on the soles) is char-
acteristic, as are painful fissures. Vesicles are absent. The condition may be confused with psoriasis, but 
there is little or none of the redness and none of the scaling or nail changes typical of psoriasis. The condi-
tion is more common in middle-aged and elderly persons and in men. The cause is unknown.11
Chronic fingertip dermatitis 
or pulpitis
This condition is characterized by dry, fissured, scaling dermatitis of the fingertips, with occasional episodes of 
vesicles. On occasion, the cause may be a contact allergy. Although the presentation is mild, this condition 
may be a considerable handicap for patients who do office work. The cause is unknown.
Nummular hand eczema This condition is notable for the round, coin-sized eczematous patches that appear on the back of the hands. 
It may be a manifestation of irritant or allergic contact dermatitis or atopic dermatitis, but often the cause 
remains unknown.
Dry, fissured hand eczema Vesicles are absent, and the condition is often a manifestation of chronic hand eczema, irrespective of the cause.
* Data are from Diepgen et al.,6 Lynde et al.,7 and Menné et al.8
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using emollients only (26%).30 However, skin atro-
phy is a risk of prolonged treatment with gluco-
corticoids. The American Academy of Dermatolo-
gy recommends daily use for 1 month followed by 
maintenance therapy two to three times per week.31 
It also recommends ointments over creams.
Topical Tacrolimus and Pimecrolimus
Although topical calcineurin inhibitors have been 
extensively investigated and are widely used to 
treat atopic dermatitis, evidence of their efficacy 
in hand eczema is limited. Side effects include a 
transient burning sensation and sensitivity to ul-
traviolet light. Pimecrolimus (applied twice daily) 
appeared to be slightly but not significantly more 
efficacious than vehicle cream alone in two large 
randomized clinical trials of 3 and 6 weeks’ dura-
tion.32,33 In a small trial conducted with patients 
who had chronic dyshidrotic palmar eczema, the 
administration of tacrolimus 0.1% twice daily re-
sulted in improvement rates of 50% or more, but 
the rates were not significantly different from 
those associated with the use of topical mometa-
sone furoate.34 In another small randomized 
trial, of 12 weeks’ duration, the use of tacrolimus 
ointment twice daily was compared with the use 
of vehicle cream alone among patients previously 
treated with a short course of oral glucocorti-
coids. The use of tacrolimus was associated with 
greater subjective improvement (as assessed by 
the patient) but was associated with no clear ben-
efit with regard to other outcomes, including the 
time to recurrence.35 In practice, one option is to 
alternate the use of these agents with topical glu-
cocorticoids.8,34
Phototherapy
Phototherapy is widely used for hand eczema, 
and in many clinics it is used as second-line 
treatment for patients in whom topical therapy 
has failed. In a 12-week trial involving 35 pa-
tients, photochemotherapy with psoralen and 
ultraviolet A (PUVA) was compared with treat-
ment with ultraviolet B (UVB) alone, both in two 
study groups and within the same patient (com-
paring a treated hand with an untreated hand). 
UVB was effective, but PUVA appeared to be more 
effective.36 In another small trial involving pa-
tients with chronic hand eczema, no significant 
difference was reported between the use of PUVA 
and UVB.37 Nausea (from the tablets of methox-
salen, a derivative of psoralen), edema, and pain 
are side effects of phototherapy. A long-term 
concern is the associated increased risk of non-
melanoma skin cancer. Instead of administering 
an oral form of psoralen, many clinics use a top-
Table 2. Differential Diagnosis of Hand Eczema.
Conditions Comments
Common conditions with an appearance similar to hand eczema
Psoriasis Lesions are dry, scaling, and sharply demarcated, and there is an absence of vesicles. 
Lesions elsewhere on the body are characteristic. Palmoplantar pustulosis, a 
variant of psoriasis, should be considered when sterile pustules are present.
Fungus A fungal infection is especially likely when one hand is more prominently involved. 
Dry scaling of the palmar creases is characteristic.
Other conditions with an appearance similar to hand eczema
Lichen planus Sharply demarcated hyperkeratotic lesions are present. This condition may mimic 
hyperkeratotic hand eczema.
Scabies Papules and burrows are present and especially likely to appear in the web spaces  
of the hands and the volar aspect of the wrists. Itchy papules are often present 
on the trunk and limbs.
Granuloma annulare Round or oval patches, with a demarcated raised edge, are characteristic and appear 
primarily on the dorsal side of the hands.
Herpes simplex In this condition, there are localized recurrent attacks of clustered vesicles, which are 
very painful but not itchy.
Self-induced lesions Self-induced skin lesions are unusual in shape and distribution.
Erythema multiforme, pityriasis 
rubra pilaris, and dermato-
myositis
These conditions are not necessarily confined to the hands. In rare cases, reactive 
scaling and hyperkeratosis of the palms are associated with cancer or diet.
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ical formulation (a cream, gel, or bath prepara-
tion).38,39 The results of two randomized trials 
showed no significant difference in efficacy be-
tween topical and oral formulations of pso-
ralen.39,40 On the basis of clinical experience, 
topical glucocorticoids are often used in combi-
nation with phototherapy, especially early in the 
course of therapy.
Oral Retinoids
Oral retinoids may be used for severe chronic hand 
eczema, in particular the hyperkeratotic subtype. 
The oral retinoid alitretinoin is approved for severe 
chronic hand eczema in several European coun-
tries and Canada (but not in the United States). In 
a randomized trial involving 1032 patients with 
chronic hand eczema (all types) that compared 
the use of 30 mg of alitretinoin daily, 10 mg of 
alitretinoin daily, and placebo for up to 24 weeks, 
the percentages of patients rating their hand ec-
zema as “clear” or “almost clear” at the end of 
therapy were 40%, 24%, and 15%, respectively.41 
Patients with hyperkeratotic eczema had the 
highest response rates to alitretinoin, but those 
with vesicular eczema also appeared to benefit, 
although formal subgroup comparisons were not 
performed. The beneficial effects of alitretinoin 
as compared with placebo were confirmed in a 
retreatment trial among a subgroup of patients 
who had had a relapse.42 Another oral retinoid, 
acitretin, administered at a dose of 30 mg per 
day, was also reported to be effective in a small 
placebo-controlled trial involving patients with 
the hyperkeratotic variant of hand eczema.43 How-
ever, cross-study comparisons of the benefits of 
acitretin and alitretinoin are not possible because 
of differences in the study designs.
Retinoids tend to be preferred over oral im-
munosuppressive agents given their better safety 
profile. Common side effects associated with 
retinoids are dry skin (especially the lips) and an 
increase in levels of blood lipids. Retinoids are 
teratogenic, so it is mandatory for women of re-
productive age to take measures to prevent preg-
nancy. Adequate contraceptive agents must be 
prescribed and a monthly pregnancy test admin-
istered; in some countries, signed informed con-
sent is required.
Oral Immunosuppressive Agents
Immunosuppressive therapy is administered in 
patients who have chronic hand eczema that is 
unresponsive to topical treatment or photothera-
py (or retinoids, when their use is appropriate). 
The use of immunosuppressive agents is based 
largely on evidence supporting their efficacy in 
the treatment of atopic dermatitis.44-46 Cyclospo-
rine is the most frequently used agent. Potential 
risks include hypertension, decreased kidney func-
tion, and sequelae of immunosuppression. The 
burden of eczema must be weighed against these 
risks.
Other agents occasionally used in practice in-
clude azathioprine, mycophenolate mofetil, and 
low-dose methotrexate,46-48 although data from 
randomized trials are lacking to assess the effi-
cacy of any of these agents in the treatment of 






Demarcated by scaling patches and the
absence of vesicles. 
Usually manifested in one hand, which
is red and dry, with scaling, especially
in the creases. 
Characterized by an unusual history, a
monomorphous picture, sharp demar-
cation, and interdigital sparing.
Characterized by sterile pustules. Also
regarded by some as a variant of pus-
tular psoriasis.
Characterized by recurrent attacks of
clustered vesicles. Painful, with no
itching. 
Characterized by an immediate reaction
(on prick test) to residual latex protein
in a medical glove; different from
allergic contact dermatitis occurring
in response to rubber additives.
Figure 2. Conditions That Mimic Hand Eczema.
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITY OF GRONINGEN on February 10, 2013. For personal use only. No other uses without permission. 
 Copyright © 2012 Massachusetts Medical Society. All rights reserved. 
clinical practice
n engl j med 367;19 nejm.org november 8, 2012 1835
hand eczema. Several weeks of azathioprine thera-
py are generally needed before there is an ap-
preciable clinical response. Short courses of oral 
glucocorticoids are used in some cases to achieve 
rapid control. All immunosuppressive agents con-
fer a risk of serious adverse events (hematologic 
and hepatic toxicity, infections, and other effects 
of long-term immunosuppressive therapy).
Areas of Uncertainty
Once hand eczema becomes chronic, classifica-
tion may be impossible. A better understanding of 
clinicopathological features of the different types 
of hand eczema may improve classification and 
the choice of therapy. Some progress has been 
made in the understanding of the role of genetic 
A BAt Presentation On Referral to Secondary Care
Obtain full history, including occupation
Determine if there was exposure to aller-
gens, irritants, or both
Rule out infection and infestation
Initiate skin-protection program that
includes avoidance of allergens or
irritants and use of topical emollients
and gloves
Initiate treatment trial with potent topical
glucocorticoid
Prescribe adequate dose and volume
Reassess in 4 wk
Check adherence and
reassess in 4 wk
Continue treatment













Consider performing prick test or
measuring serum IgE level if reactions
to proteins (e.g., food)
Review management and skin protection
Modify type and dose of topical
glucocorticoid
Consider tacrolimus
Provide patient with information tailored
to individual needs
Tailor treatment to individual needs
If no improvement, initiate systemic
(oral) treatment




short courses of oral
glucocorticoids





Figure 3. Management of Hand Eczema.
Clinical opinion differs with regard to the place of psoralen and ultraviolet A (PUVA) in treatment; it is often used before systemic treat-
ment. Data are from English et al.22
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and epigenetic changes in skin-barrier func-
tion49; further research in this area might help to 
identify patients who may benefit from barrier-
strengthening strategies as opposed to antiin-
flammatory or immunosuppressive treatment.
Additional data from randomized trials are 
needed to assess and compare the various thera-
pies used for chronic hand eczema. More data are 
needed to inform the role of alitretinoin in the 
treatment of vesicular hand eczema.
Guidelines
Guidelines have been published by professional 
medical societies in a few countries, including 
Denmark and Germany.8,20 In addition, there is a 
consensus statement from the United Kingdom22 
and a guideline from a Canadian group of ex-
perts.7 The American Academy of Dermatology 
has published guidelines on the use of topical 
glucocorticoids, the mainstay of treatment for 
hand eczema.31 A British guideline on photother-
apy includes a comment on the use of photother-
apy in hand eczema.38 The recommendations 
presented here are largely consistent with these 
guidelines and consensus statements.
Conclusions  
and Recommendations
The patient described in the vignette has vesicular-
type atopic hand eczema. Her household, which 
includes small children, and her job as a nurse, 
which requires frequent hand washing and the 
use of occlusive gloves, are sources of continued 
exposure to irritants. Patch testing is recommend-
ed to rule out contact allergy to rubber compo-
nents in medical gloves and to preservatives in 
liquid cleansers. Contact allergy to nickel, diag-
nosed by means of patch testing, is often observed 
in women, but its relevance to the cause of this 
patient’s hand eczema is uncertain. Prick testing 
is not necessary.
Patients such as the one described should be 
counseled to avoid — or at least dramatically 
reduce — exposure to irritants (and contact al-
lergens, when detected by patch testing) and 
should inform their employer of the recommen-
dations. For this patient, I would recommend the 
use of impermeable gloves with a cotton lining 
when performing “wet” tasks. Frequent applica-
tion of emollients (preferably ointments) is an 
essential part of management, in combination 
with application of potent topical glucocorticoids 
once or twice daily for at least 4 weeks. If topical 
glucocorticoids are not effective and the patient 
has access to PUVA treatment, I would recom-
mend a course of PUVA combined with topical 
glucocorticoids. A short course (1 week) of oral 
glucocorticoids may be needed to achieve rapid 
control; long-term use is not recommended, given 
the adverse effects. For severe cases of hand ec-
zema that are unresponsive to topical therapy or 
PUVA, oral cyclosporine may be considered. Other 
immunosuppressive agents are also an option, 
although they are used less frequently.
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